{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:14:49Z","timestamp":1778825689809,"version":"3.51.4"},"reference-count":8,"publisher":"Japanese Circulation Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2021,10,8]]},"DOI":"10.1253\/circrep.cr-21-0068","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T22:08:42Z","timestamp":1630706922000},"page":"589-593","source":"Crossref","is-referenced-by-count":5,"title":["Initial Real-World Practical Experience of Sacubitril\/Valsartan Treatment in Japanese Patients With Chronic Heart Failure"],"prefix":"10.1253","volume":"3","author":[{"given":"Makiko","family":"Nakamura","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Joho","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. <i>JACC Heart Fail<\/i> 2014; 2: 663\u2013670.","DOI":"10.1016\/j.jchf.2014.09.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med<\/i> 2014; 371: 993\u20131004.","DOI":"10.1056\/NEJMoa1409077"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, et al. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. <i>Circulation<\/i> 2020; 141: 352\u2013361.","DOI":"10.1161\/CIRCULATIONAHA.119.044586"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Ohishi T, et al. Efficacy and safety of sacubitril\/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. <i>J Cardiol<\/i> 2017; 70: 225\u2013231.","DOI":"10.1016\/j.jjcc.2016.11.011"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction: Results from the PARALLEL-HF study. <i>Circ J<\/i> 2021; 85: 548\u2013594.","DOI":"10.1253\/circj.CJ-20-0854"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. B\u00f6hm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF. <i>Eur Heart J<\/i> 2017; 38: 1132\u20131143.","DOI":"10.1093\/eurheartj\/ehw570"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, et al. Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: The PARADIGM-HF trial. <i>Eur J Heart Fail<\/i> 2016; 18: 1228\u20131234.","DOI":"10.1002\/ejhf.580"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, et al. Sacubitril\/valsartan and sudden cardiac death according to implantable cardioverter-defibrillator use and heart failure cause: A PARADIGM-HF analysis. <i>JACC Heart Fail<\/i> 2020; 8: 844\u2013855.","DOI":"10.1016\/j.jchf.2020.06.015"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/3\/10\/3_CR-21-0068\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T03:52:37Z","timestamp":1633751557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/3\/10\/3_CR-21-0068\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":8,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-21-0068","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"article-number":"CR-21-0068"}}